These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2156298

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Polymorphism of enzymes involved in drug metabolism: gene structure and enzymatic activity].
    Krynetskiĭ EI.
    Mol Biol (Mosk); 1996; 30(1):33-42. PubMed ID: 8714120
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Genetic polymorphisms of drug metabolism.
    Meyer UA.
    Fundam Clin Pharmacol; 1990; 4(6):595-615. PubMed ID: 1982880
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A nomenclature system for metabolic gene polymorphisms.
    Garte S, Crosti F.
    IARC Sci Publ; 1999; (148):5-12. PubMed ID: 10493244
    [Abstract] [Full Text] [Related]

  • 31. [Adverse drug reactions. Hereditary differences in drug metabolism].
    Collette D, Thürmann PA.
    Dtsch Med Wochenschr; 2002 May 10; 127(19):1025-8. PubMed ID: 11997871
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease.
    Black C, May G, Csuka ME, Lupoli S, Wilkinson GR, Branch RA.
    Clin Pharmacol Ther; 1992 Dec 10; 52(6):659-67. PubMed ID: 1458774
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.
    Touw DJ.
    Drug Metabol Drug Interact; 1997 Dec 10; 14(2):55-82. PubMed ID: 9893738
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Is genetic testing for cytochrome P450 polymorphisms ready for implementation?
    Matchar DB, Thakur M.
    Am Fam Physician; 2007 Aug 01; 76(3):348, 351. PubMed ID: 17708133
    [No Abstract] [Full Text] [Related]

  • 38. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.
    Alvan G, Bertilsson L, Dahl ML, Ingelman-Sundberg M, Sjöqvist F.
    Drug Metab Dispos; 2001 Apr 01; 29(4 Pt 2):580-5. PubMed ID: 11259356
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cola and cough syrup used to determine abnormal drug metabolism.
    Oncology (Williston Park); 1989 Nov 01; 3(11):111-2. PubMed ID: 2641308
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.